Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01741545 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 71
- Enrollment target
NCT01741545 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 71 participants.
The verdict
NCT01741545, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 71 participants
- Enrollment target
Study Summary
The primary objective for this study is to evaluate the proportion of subjects who achieve SVR12 (HCV RNA \< LLOQ (target not detected) at post-treatment follow-up Week 12 in subjects with Genotype(GT)-1b, -4 and GT-2, -3
Interventions
- DRUG Ribavirin
- DRUG Daclatasvir
- BIOLOGICAL Pegylated-Interferon-lambda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2013-03-31 |
| Est. Completion | 2015-01-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01741545
The ClinicalTrials.gov registry entry for NCT01741545 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ribavirin is the first listed.
NCT01741545 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01741545 about?
NCT01741545 is a clinical study titled "Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia". The primary objective for this study is to evaluate the proportion of subjects who achieve SVR12 (HCV RNA \< LLOQ (target not detected) at post-treatment follow-up Week 12 in subjects with Genotype(GT)-1b, -4 and GT-2, -3
What is the current status of trial NCT01741545?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 71 participants. The study started on 2013-03-31. Estimated completion is 2015-01-31.
What interventions are being tested in trial NCT01741545?
The interventions under investigation include: Ribavirin (DRUG), Daclatasvir (DRUG), Pegylated-Interferon-lambda (BIOLOGICAL).
Who is sponsoring clinical trial NCT01741545?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.